OCA
ABVX

Octagon Capital Advisors’s Abivax ABVX Stock Holding History

Octagon Capital Advisors’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75.4M Sell
677,000
-79,000
-10% -$9.35M 8.34% 3
2025
Q4 		$102M Sell
756,000
-569,000
-43% -$62.1M 12.38% 1
2025
Q3 		$112M Buy
1,325,000
+58,000
+5% +$3.56M 17.05% 1
2025
Q2 		$9.69M Buy
1,267,000
+37,000
+3% +$241K 2.13% 20
2025
Q1 		$7.69M Buy
+1,230,000
New +$8.32M 1.49% 26

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

Octagon Capital Advisors's ABVX Position: Q1 2026 in Review

Octagon Capital Advisors reduced its Abivax (ABVX) stake by 10% in Q1 2026, selling an estimated $9.35M and leaving 677,000 shares worth $75.4M. The position accounts for 8.34% of the portfolio, ranked #3.

Octagon Capital Advisors first reported a position in ABVX in Q1 2025 and has held it in 5 quarters since. The position peaked at $112M in Q3 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

  • Octagon Capital Advisors held 677,000 shares of Abivax worth $75.4M as of Q1 2026.
  • Octagon Capital Advisors sold 79,000 Abivax shares in Q1 2026, an estimated $9.35M.
  • Abivax made up 8.34% of Octagon Capital Advisors's portfolio in Q1 2026, its #3 holding.
  • Octagon Capital Advisors first reported a position in Abivax in Q1 2025 and has held it in 5 quarters since.
  • Octagon Capital Advisors's Abivax position peaked at $112M in Q3 2025.
  • 254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Octagon Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.